Clinical Trial Finder

Inclusion Criteria:

1. Patients must have unifocal glioblastoma (grade IV astrocytoma, WHO classification). The GBM can be:

• - Or resectable and the patient has received curative surgery.

• - Or unresectable, and the largest tumor diameter (contrast enhancement) must be less than 5 cm on MRI.

2. In all cases, the diagnosis must be confirmed by a pathologist. In patients for whom surgery is not possible, the diagnosis is confirmed by a biopsy of tumor tissue. 3. Methylation status of MGMT gene promoter is known. 4. Patients who have undergone resection should have received an MRI or a scan after surgery in order to visualize residual tumor. If not, the operative report must be available. 5. Surgery or biopsy must have occurred 45 days before the start of radiotherapy. 6. WHO ≤ 2. 7. Age ≥ 18 years. 8. Signed Consent collected before any specific procedure in the study. 9. Patient member in a national insurance scheme.

Exclusion Criteria:

1. Signs of hemorrhage on pre-radiotherapy MRI preventing a good spectrometric analysis. 2. Patient with multifocal glioblastoma. 3. Tumor located within 2 cm of the optic chiasm. 4. Patient with leptomeningeal metastases, 5. patients prone to epileptic seizures despite treatment with anticonvulsant. 6. Patients who received other previous treatment for glioblastoma multiforme. 7. Abnormal haematological results at inclusion with:

• - Neutrophils < 1500/mm3.

• - Blood-platelets < 100000/mm3.

8. Severe or chronic renal insufficiency (creatinin clearance ≤ 30 ml/min calculated using Cockroft-Gault's formula. 9. Patient unable to follow procedures, visits, examinations described in the study. 10. Any usual formal indication against imaging examinations (important claustrophobia, pace maker ...) 11. Pregnant women or nursing mothers can not participate in the study. Women of childbearing age must have a negative pregnancy test within 72 hours prior to study entry. 12. Men and women of childbearing age must use effective contraception at study entry and throughout the study. 13. Any concomitant or previous malignant disease within 5 years prior to study entry. 14. Any prior systemic chemotherapy within 5 years prior to inclusion (for malignant disease in medical history) 15. Any other medical conditions making the inclusion of the patient in the study inappropriate in the opinion of the investigator. 16. Patient under legal guardianship

Arms

Active Comparator: Conventional arm

3-dimensional conformal radiotherapy + Temozolomide

Experimental: Experimental arm

simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide

Interventions

Radiation: - Radiotherapy

Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging. - Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie : - during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day, - post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.

Radiation: - Experimental arm

Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed - Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie : - during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day, - post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.